Valeant Pharmaceuticals International (NYSE:VRX) announced today that it plans to buy Russian over-the-counter drug maker Natur Produckt International for $180 million with $5 million in future milestones.The Canadian drug maker says the deal will expand its presence in Russia and should bring pro forma revenue from Russian operations up to approximately $175 million.Valeant Pharmaceuticals International (NYSE:VRX) has potential upside of 10.9% based on a current price of $54.64 and an average consensus analyst price target of $60.6.